Pharming Group NV Q2 2024 Earnings Call Transcript - Seeking Alpha
| PHAR Stock | USD 10.49 0.47 4.69% |
Slightly above 55% of Pharming Group's retail investors are presently thinking to get in. The analysis of overall sentiment of trading Pharming Group NV stock suggests that some investors are interested at this time. Pharming Group's investing sentiment overview a quick insight into current market opportunities from investing in Pharming Group NV. Many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Pharming Group NV Q2 2024 Earnings Call Transcript Seeking Alpha
Read at news.google.com
 |
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Pharming Group is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
| ANEB | Anebulo Pharmaceuticals | 10.89 | ||||
| FENC | Fennec Pharmaceuticals | 6.80 | ||||
| LRMR | Larimar Therapeutics | 5.64 | ||||
| GNTA | Genenta Science | 3.49 | ||||
| MLYS | Mineralys Therapeutics, | 3.48 | ||||
| PRTC | PureTech Health | 2.95 | ||||
| RZLT | Rezolute | 1.52 | ||||
| MOLN | Molecular Partners | 0.25 | ||||
| JANX | Janux Therapeutics | 2.48 | ||||
| VRCA | Verrica Pharmaceuticals | 3.03 | ||||
| ACRV | Acrivon Therapeutics, | 8.00 |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.